ARTICLE | Clinical News
Thalomid thalidomide: Phase II data; marketed to treat erythema nodosum leprosum in leprosy
November 8, 1999 8:00 AM UTC
University College London researchers presented data from 66 advanced cancer patients given 100 mg Thalomid per day until disease progression or unacceptable toxicity occurred. Partial responses were seen in 3 of 18 renal cancer patients. Disease stabilization was seen in 3 additional renal cancer patients, as well as in 4 of 17 melanoma patients. No other objective responses were seen. ...